Log in for full access to this activity, if you are registered.

Registration Options

Activity Dates: 06/12/2014 - 04/28/2017

Target Audience

This course is designed for pharmacists, nurse practitioners or other healthcare professionals involved in the comprehensive medication management of psychiatric and/or neurological patients.

Session Summary

Drug shortages are becoming ever more common the United States, with the number of drug shortages nearly tripling between 2005 and 2010. For the period from January through October 2011, the Food and Drug Administration reported 220 drug shortages, most commonly involving generic injectable medications.  Shortages of injectable medications used during electroconvulsive therapy (ECT) are of particular concern due to the limited available alternatives. This was evidenced when methohexital, considered the “gold standard” anesthetic for ECT procedures, was on national shortage from 2002-2003.

The impact of medication shortages on the availability of ECT poses a significant challenge to clinicians. Because ECT is a short procedure, standard practice is to use very short-acting anesthetic and neuromuscular blocking agents. Potential alternative anesthetic and neuromuscular blocking agents may have substantial clinical impact due to differential pharmacokinetic and/or pharmacodynamic properties. Amy M. VandenBerg, PharmD, BCPP, will discuss the pharmacology and evidence-based alternatives for induction agents, neuromuscular blockers, and adjunctive agents for ECT to enable pharmacists and other clinicians to make the best choices and recommendations in the setting of national drug shortages.

Course Requirements

You will proceed through the following steps to satisfactorily complete this course:

  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date. (login first)
  • Complete the evaluation at the end of the activity. (login first)
  • If necessary, complete the post-test retest no later than the closing activity date. (login first)
  • Receive a passing grade (70%).
  • Provide the necessary details in your profile to ensure correct reporting by CPNP to CPE Monitor. (login first)

This course is provided online at cpnp.org and consists of the speaker audio and slides. A PDF file of the slides is also provided and access is available to participants indefinitely although ACPE credit is available only through the course expiration date.

Participants in this course must complete an examination and achieve a score of 70% or greater. Successful completion of the course also requires the completion of a course evaluation. ACPE statements of credit can be retrieved by participants online at cpnp.org immediately upon successful completion of the course.

Faculty Information and Disclosures

Learning Objectives

  1. Analyze the reasons for and impact of recent and ongoing shortages of medications commonly used in electroconvulsive therapy (ECT).
  2. Compare first-line medication options for ECT to available second-line alternatives.
  3. Develop an educational plan for staff to prevent potential medication errors when substituting alternative agents for ECT during a drug shortage crisis.
  4. Recommend a process to ensure appropriate alternative agents used in ECT are obtained from reputable sources during drug shortages.

Continuing Education Credit and Disclosures

Activity Dates: 06/12/2014 - 04/28/2017
ACPE Contact Hours: 1.0
ACPE Number: 0284-0000-14-011-H01-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This self-study course provides 1.0 contact hours (0.10 CEUs) of application-based continuing education credit from CPNP approved programming. The ACPE universal program number assigned to this course is 0284-0000-14-011-H01-P (1.0 contact hours).

Grant Support

This activity is supported by an educational grant from Sunovion Pharmaceuticals, Inc. and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.